Literature DB >> 21307957

Functional magnetic resonance imaging reveals different neural substrates for the effects of orexin-1 and orexin-2 receptor antagonists.

Alessandro Gozzi1, Giuliano Turrini, Laura Piccoli, Mario Massagrande, David Amantini, Marinella Antolini, Prisca Martinelli, Nicola Cesari, Dino Montanari, Michela Tessari, Mauro Corsi, Angelo Bifone.   

Abstract

Orexins are neuro-modulatory peptides involved in the control of diverse physiological functions through interaction with two receptors, orexin-1 (OX1R) and orexin-2 (OX2R). Recent evidence in pre-clinical models points toward a putative dichotomic role of the two receptors, with OX2R predominantly involved in the regulation of the sleep/wake cycle and arousal, and the OX1R being more specifically involved in reward processing and motivated behaviour. However, the specific neural substrates underlying these distinct processes in the rat brain remain to be elucidated. Here we used functional magnetic resonance imaging (fMRI) in the rat to map the modulatory effect of selective OXR blockade on the functional response produced by D-amphetamine, a psychostimulant and arousing drug that stimulates orexigenic activity. OXR blockade was produced by GSK1059865 and JNJ1037049, two novel OX1R and OX2R antagonists with unprecedented selectivity at the counter receptor type. Both drugs inhibited the functional response to D-amphetamine albeit with distinct neuroanatomical patterns: GSK1059865 focally modulated functional responses in striatal terminals, whereas JNJ1037049 induced a widespread pattern of attenuation characterised by a prominent cortical involvement. At the same doses tested in the fMRI study, JNJ1037049 exhibited robust hypnotic properties, while GSK1059865 failed to display significant sleep-promoting effects, but significantly reduced drug-seeking behaviour in cocaine-induced conditioned place preference. Collectively, these findings highlight an essential contribution of the OX2R in modulating cortical activity and arousal, an effect that is consistent with the robust hypnotic effect exhibited by JNJ1037049. The subcortical and striatal pattern observed with GSK1059865 represent a possible neurofunctional correlate for the modulatory role of OX1R in controlling reward-processing and goal-oriented behaviours in the rat.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21307957      PMCID: PMC3030585          DOI: 10.1371/journal.pone.0016406

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  51 in total

1.  Orexin, drugs and motivated behaviors.

Authors:  Thomas E Scammell; Clifford B Saper
Journal:  Nat Neurosci       Date:  2005-10       Impact factor: 24.884

2.  In vivo mapping of functional connectivity in neurotransmitter systems using pharmacological MRI.

Authors:  Adam J Schwarz; Alessandro Gozzi; Torsten Reese; Angelo Bifone
Journal:  Neuroimage       Date:  2006-12-26       Impact factor: 6.556

3.  Study-level wavelet cluster analysis and data-driven signal models in pharmacological MRI.

Authors:  Adam J Schwarz; Brandon Whitcher; Alessandro Gozzi; Torsten Reese; Angelo Bifone
Journal:  J Neurosci Methods       Date:  2006-08-28       Impact factor: 2.390

Review 4.  The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness.

Authors:  Takeshi Sakurai
Journal:  Nat Rev Neurosci       Date:  2007-02-14       Impact factor: 34.870

5.  Promotion of sleep by targeting the orexin system in rats, dogs and humans.

Authors:  Catherine Brisbare-Roch; Jasper Dingemanse; Ralf Koberstein; Petra Hoever; Hamed Aissaoui; Susan Flores; Celia Mueller; Oliver Nayler; Joop van Gerven; Sanne L de Haas; Patrick Hess; Changbin Qiu; Stephan Buchmann; Michael Scherz; Thomas Weller; Walter Fischli; Martine Clozel; François Jenck
Journal:  Nat Med       Date:  2007-01-28       Impact factor: 53.440

6.  A multimodality investigation of cerebral hemodynamics and autoregulation in pharmacological MRI.

Authors:  Alessandro Gozzi; Laura Ceolin; Adam Schwarz; Torsten Reese; Simone Bertani; Valerio Crestan; Angelo Bifone
Journal:  Magn Reson Imaging       Date:  2007-04-23       Impact factor: 2.546

Review 7.  Linking nucleus accumbens dopamine and blood oxygenation.

Authors:  Brian Knutson; Sasha E B Gibbs
Journal:  Psychopharmacology (Berl)       Date:  2007-02-06       Impact factor: 4.530

8.  Determining the potency and molecular mechanism of action of insurmountable antagonists.

Authors:  Terry Kenakin; Stephen Jenkinson; Christian Watson
Journal:  J Pharmacol Exp Ther       Date:  2006-07-20       Impact factor: 4.030

9.  A role for lateral hypothalamic orexin neurons in reward seeking.

Authors:  Glenda C Harris; Mathieu Wimmer; Gary Aston-Jones
Journal:  Nature       Date:  2005-08-14       Impact factor: 49.962

10.  1,2,4-triazol-3-yl-thiopropyl-tetrahydrobenzazepines: a series of potent and selective dopamine D(3) receptor antagonists.

Authors:  Fabrizio Micheli; Giorgio Bonanomi; Frank E Blaney; Simone Braggio; Anna Maria Capelli; Anna Checchia; Ornella Curcuruto; Federica Damiani; Romano Di Fabio; Daniele Donati; Gabriella Gentile; Andy Gribble; Dieter Hamprecht; Giovanna Tedesco; Silvia Terreni; Luca Tarsi; Andrew Lightfoot; Geoff Stemp; Gregor Macdonald; Alex Smith; Michela Pecoraro; Marcella Petrone; Ornella Perini; Jacqui Piner; Tino Rossi; Angela Worby; Maria Pilla; Enzo Valerio; Cristiana Griffante; Manolo Mugnaini; Martyn Wood; Claire Scott; Michela Andreoli; Laurent Lacroix; Adam Schwarz; Alessandro Gozzi; Angelo Bifone; Charles R Ashby; Jim J Hagan; Christian Heidbreder
Journal:  J Med Chem       Date:  2007-09-15       Impact factor: 7.446

View more
  37 in total

Review 1.  The hypocretins/orexins: integrators of multiple physiological functions.

Authors:  Jingcheng Li; Zhian Hu; Luis de Lecea
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

2.  Effect of 1-substitution on tetrahydroisoquinolines as selective antagonists for the orexin-1 receptor.

Authors:  David A Perrey; Nadezhda A German; Ann M Decker; David Thorn; Jun-Xu Li; Brian P Gilmour; Brian F Thomas; Danni L Harris; Scott P Runyon; Yanan Zhang
Journal:  ACS Chem Neurosci       Date:  2015-02-12       Impact factor: 4.418

3.  Hypocretin receptor 1 blockade preferentially reduces high effort responding for cocaine without promoting sleep.

Authors:  Zachary D Brodnik; David L Bernstein; Courtney D Prince; Rodrigo A España
Journal:  Behav Brain Res       Date:  2015-06-03       Impact factor: 3.332

Review 4.  Multiple roles for orexin/hypocretin in addiction.

Authors:  Stephen V Mahler; Rachel J Smith; David E Moorman; Gregory C Sartor; Gary Aston-Jones
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

Review 5.  Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA?

Authors:  Shaun Yon-Seng Khoo; Robyn Mary Brown
Journal:  CNS Drugs       Date:  2014-08       Impact factor: 5.749

6.  A selective orexin-1 receptor antagonist attenuates stress-induced hyperarousal without hypnotic effects.

Authors:  Pascal Bonaventure; Sujin Yun; Philip L Johnson; Anantha Shekhar; Stephanie D Fitz; Brock T Shireman; Terry P Lebold; Diane Nepomuceno; Brian Lord; Michelle Wennerholm; Jonathan Shelton; Nicholas Carruthers; Timothy Lovenberg; Christine Dugovic
Journal:  J Pharmacol Exp Ther       Date:  2015-01-12       Impact factor: 4.030

7.  Synthesis and Evaluation of Orexin-1 Receptor Antagonists with Improved Solubility and CNS Permeability.

Authors:  David A Perrey; Ann M Decker; Yanan Zhang
Journal:  ACS Chem Neurosci       Date:  2017-11-20       Impact factor: 4.418

Review 8.  Therapeutics development for addiction: Orexin-1 receptor antagonists.

Authors:  David A Perrey; Yanan Zhang
Journal:  Brain Res       Date:  2018-08-24       Impact factor: 3.252

9.  The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors.

Authors:  Géraldine M Mang; Thomas Dürst; Hugo Bürki; Stefan Imobersteg; Dorothee Abramowski; Edi Schuepbach; Daniel Hoyer; Markus Fendt; Christine E Gee
Journal:  Sleep       Date:  2012-12-01       Impact factor: 5.849

10.  Diurnal inhibition of NMDA-EPSCs at rat hippocampal mossy fibre synapses through orexin-2 receptors.

Authors:  Martina Perin; Fabio Longordo; Christine Massonnet; Egbert Welker; Anita Lüthi
Journal:  J Physiol       Date:  2014-08-01       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.